Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer's Disease.

ABSTRACT:

Background

Intranasally administered insulin has shown promise in both rodent and human studies in Alzheimer's disease; however, both effects and mechanisms require elucidation.

Objective

We assessed the effects of intranasally administered insulin on white matter health and its association with cognition and cerebral spinal fluid biomarker profiles in adults with mild cognitive impairment or Alzheimer's disease in secondary analyses from a prior phase 2 clinical trial (NCT01767909).

Design

A randomized (1:1) double-blind clinical trial.

Setting

Twelve sites across the United States.

Participants

Adults with mild cognitive impairment or Alzheimer's disease.

Intervention

Participants received either twice daily placebo or insulin (20 IU Humulin R U

SUBMITTER: Kellar D 

PROVIDER: S-EPMC10233712 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature